anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the application of succinic acid in preparing medicines with an antianxiety effect, which has good curative effect and has no side effects of mitigation, hypnogenesis, vertigo, excitation, nausea, etc. In the application of succinic acid for preparing medicines for preventing and curing anxiety, the succinic acid can be succinic salt, succinic ester, succinic acyl halide, and succinic acid anhydride which are acceptable in pharmacy. Various medical carriers can be added in the succinic acid to prepare a medical composition. The medical composition can be taken through oral administration, parenteral administration or local path administration. The medicament forms of the medical composition can be tablets, capsules, solutions, suspended solvate, injections, instilment liquid, etc. The present invention provides a new way for the application of the succinic acid.
Chronic rhinosinusitis (CRS) has recently undergone a significant paradigm shift, moving from a phenotypical classification towards an "endotype-based" definition that places more emphasis on clinical and therapeutic aspects. Similar to other airway diseases, like asthma, most cases of CRS in developed countries exhibit a dysregulated type-2 immune response and related cytokines. Consequently, the traditional distinction between upper and lower airways has been replaced by a "united airway" perspective. Additionally, type-2 related disorders extend beyond respiratory boundaries, encompassing conditions beyond the airways, such as atopic dermatitis. This necessitates a multidisciplinary approach. Moreover, consideration of possible systemic implications is crucial, particularly in relation to sleep-related breathing diseases like Obstructive Sleep Apnoea Syndrome (OSAS) and the alteration of systemic inflammatory mediators such as nitric oxide. The trends in epidemiological, economic, and social burden are progressively increasing worldwide, indicating syndemic characteristics. In light of these insights, this narrative review aims to present the latest evidence on respiratory type-2 related disorders, with a specific focus on CRS while promoting a comprehensive perspective on the "united airways". It also introduces a novel concept: viewing these conditions as a multiorgan, systemic, and syndemic disease.
PURPOSE: A composition for immunity sterengthening is provided to strengthen immunity by having a Selaginellar tamariscina Spring extract or a fraction of a Selaginellar tamariscina Spring extract as an active ingredient. CONSTITUTION: A composition for immunity strengthening contains a Selaginellar tamariscina Spring extract or a fraction of a Selaginellar tamariscina Spring extract as an active ingredient. The composition contains a 0.02-50 weight% of the Selaginellar tamariscina Spring extract or the fraction of the Selaginellar tamariscina Spring extract per total weight of the composition. The Selaginellar tamariscina Spring extract is extracted using low quality alcohols ranged from C1 to C4 or a mixed solvent thereof. The low quality alcohols in with C1-C4 are methanol or ethanol. The Selaginellar tamariscina Spring extract fraction is fractionated using a non-polar or polar organic solvent. [Reference numerals] (AA) Leukocyte count; (BB,CC) Experimental group; (DD) Control group; (EE) Day seven; (FF) Day fourteen
The invention relates to pharmaceutics and more specifically to a process of manufacturing a drug product for regulation of metabolic processes associated with potassium and magnesium deficiency. The drug product may be used in therapy, e.g. in cardiology and in sports medicine. The invention proposes a pharmaceutical composition with delayed and sustained release comprising a mixture of potassium and magnesium salts of asparagine acid presented as racemates and/or isomers thereof and/or a mixture thereof. The pharmaceutical composition represents a solid dosage form characterized by targeted release of the active substance and consisting of a core and a shell as a film coating. Pharmacokinetic benefits consist in lower side effects on the gastric mucosa. This is achieved by applying a specially-composed shell that is soluble in the alkaline intestinal medium, and this is also due to the optimally developed ratio of active ingredients and excipients both in the core and in the shell, namely: filler, disintegrant, anti-friction agent - in the core; release modifier, plasticizer, anti-friction agent and coloring agent - in the shell of the solid dosage form.
Process for permanent deformation of hair comprises: (i) mixing (a) a powder composition comprising at least one keratin-reducing agent which is solid or is adsorbed on a solid with (b) an aqueous liquid composition not containing a keratin-reducing agent; (ii) applying the mixture to the hair before, during or after an optional step of putting the hair under tension; (iii) allowing time for disulphide bonds in the hair to be reduced; (iv) applying a fixing composition containing at least one oxidising agent; (v) allowing time for permanent deformation; and (vi) rinsing the hair. Also claimed is a product comprising components (a) and (b) as above. Preferably the solid keratin-reducing agent is a sulphite or thiol, especially cysteine or cysteamine. The keratin-reducing agent adsorbed on a solid is thioglycolic or thiolactic acid adsorbed on a particulate solid selected from silica, clays, carbohydrates and organic polymers. The powder composition can also contain a thickener selected from guar gum, Tara gum and picea flour "farine d'epicea". The powder composition can also contain powdered polymers, alkaline and/or acids. The mixture contains 1-25 wt.% reducing agent. The mixture comprises 1-80 wt.% of the powder composition and 20-99 wt.% of the liquid composition. The mixture can also contain up to 30 wt.% surfactant. The mixture can also contain silicones, waxes, polymers, penetrants, swelling agents, (di)alkylene glycol ethers, alkanediols, fatty acids, lanolin derivatives, ceramides, active ingredients, hair loss inhibitors, antidandruff agents, suspension aids, sequestrants, opacifiers, dues, solar filters, perfumes etc..
In Period 1, participants will receive a single dose of prednisone 25 mg (20 mg + 5 mg) tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT125236 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT125236 and the prandial state will be determined after evaluation of safety and PK data from Part 1. Part 3 of the study is optional.
This is a randomized phase II study. The primary goal of this study is two-fold; one is to determine the safety and tolerability of three monthly pBI-11 DNA administrations in each thigh of patients with persistent HPV16 and/or HPV18+ \< cervical intraepithelial neoplasia 2 (CIN2), wherein either 0.1 mL (0.3 mg) of the plasmid DNA is administered intradermally (I.D.) into each thigh (for a total of 0.6 mg DNA at each visit) using a Pharmajet Tropis device, or 0.5 mL (1.5 mg) of the plasmid DNA is administered intramuscularly (I.M.) into each thigh (for a total of 3 mg DNA at each visit) using a Pharmajet Stratis device; and the other is to evaluate the effect of vaccine on (HPV16/18) viral DNA clearance. Secondary goals are to seek preliminary evidence of prevention of disease progression and assess induction of an HPV16/18-specific immune response to select the appropriate regimen for a subsequent phase III clinical trial. Persistence is defined as positivity on two sequential tests. A total of 72 participants will be enrolled in 4 arms of the study in a 2:1:2:1 ratio (24 patients randomized to the intervention and 12 patient randomized to placebo via Tropis device, and 24 patients randomized to the intervention and 12 patient randomized to placebo via Stratis device).
Extensive stage SCLC patients receiving first-line chemotherapy plus PD-(L)1 antibody treatment will be enrolled in this cohort. Baseline tumor tissue samples and peripheral blood samples will be collected for transcriptome and immunohistochemistry analysis etc.
The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2/sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay. In addition, the compounds of the present invention also demonstrated to have potent anti-angiogenic effects toward endothelial cells (HUVEC) and inhibit angiogenesis in vitro, ex vivo and in vivo. The dual inhibitors of the present invention also demonstrate anti-angiogenic effect to slow breast tumor growth in vivo.
Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
Tremendous technological advances have occurred in recent years that enable easily controlled lights, sound, temperature, airflow as well as sensatory experiences such as smell or vibrations. While in some fields, these technologies are readily used, their potential application within healthcare environments has not yet been studied. In this study, we want to investigate how environmental factors including light, sound, temperature, smell, and sensatory experiences such as vibration are being perceived by subjects to develop environmental strategies using those components to create a more relaxing, and comforting experience for patients prior, during and after an imaging examination and for staff working in such environments. This data that will also guide to encourage changes of patient staff facility interactions to further improve the healthcare experience and quality of imaging examinations. To get a complete set of data, we plan to include volunteer participants, patients scheduled for imaging examinations, and staff working in the healthcare environment. This study has up to three different components: A, filling out survey forms to learn more about the perception of experience factors B, participating in facility experiences that may expose subjects to different facility factors and will then assess responses using additional survey forms or electronic measurement and data capture devices and C, during an imaging study the environment experience may be altered and assessments will be done to determine how relaxed the subject remains during the imagining study and the degree of motion induced artifacts. Feedback data will be obtained through survey tools as well as available consumer grade wearable devices that can continuously capture physiological parameters such as heart rate, motion, body perspiration and muscle tension. Only participants in the patient, staff, or volunteer populations who are not receiving an MRI imaging examination will participate in utilizing the wearable devices, as the wearable devices are not compatible with the MRI system. Patients receiving a PET/CT examination will be able to utilize a wearable device. For patients scheduled for an imaging examination the findings and perception of environmental factors will be compared with the image quality of the imaging examination and the feedback responses.
Frontotemporal dementia (FTD) is an early-onset neurodegenerative disorder with a heterogeneous clinical presentation. Verbal fluency is regularly used as a sensitive measure of language ability, semantic memory, and executive functioning, but qualitative changes in verbal fluency in FTD are currently overlooked. This retrospective study examined qualitative, linguistic features of verbal fluency in 137 patients with behavioral variant (bv)FTD (n = 50), or primary progressive aphasia (PPA) [25 non-fluent variant (nfvPPA), 27 semantic variant (svPPA), and 34 logopenic variant (lvPPA)] and 25 control participants. Between-group differences in clustering, switching, lexical frequency (LF), age of acquisition (AoA), neighborhood density (ND), and word length (WL) were examined in the category and letter fluency with analysis of variance adjusted for age, sex, and the total number of words. Associations with other cognitive functions were explored with linear regression analysis. The results showed that the verbal fluency performance of patients with svPPA could be distinguished from controls and other patient groups by fewer and smaller clusters, more switches, higher LF, and lower AoA (all p < 0.05). Patients with lvPPA specifically produced words with higher ND than the other patient groups (p < 0.05). Patients with bvFTD produced longer words than the PPA groups (p < 0.05). Clustering, switching, LF, AoA, and ND-but not WL-were differentially predicted by measures of language, memory, and executive functioning (range standardized regression coefficient 0.25-0.41). In addition to the total number of words, qualitative linguistic features differ between subtypes of FTD. These features provide additional information on lexical processing and semantic memory that may aid the differential diagnosis of FTD.
PURPOSE: Stomach and esophageal cancers are among the highest mortality from cancers worldwide. Microbiota has an interplaying role within the human gastrointestinal (GI) tract. Dysbiosis occurs when a disruption of the balance between the microbiota and the host happens. With this narrative review, we discuss the main alterations in the microbiome of gastroesophageal cancer, revealing its potential role in the pathogenesis, early detection, and treatment.
RESULTS: Helicobacter pylori plays a major role the development of a cascade of preneoplastic conditions ranging from atrophic gastritis to metaplasia and dysplasia, ultimately culminating in gastric cancer, while other pathogenic agents are Fusobacterium nucleatum, Bacteroides fragilis, Escherichia coli, and Lactobacillus. Campylobacter species (spp.)'s role in the progression of esophageal adenocarcinoma may parallel that of Helicobacter pylori in the context of gastric cancer, with other esophageal carcinogenic agents being Escherichia coli, Bacteroides fragilis, and Fusobacterium nucleatum. Moreover, gut microbiome could significantly alter the outcomes of chemotherapy and immunotherapy. The gut microbiome can be modulated through interventions such as antibiotics, probiotics, or prebiotics intake. Fecal microbiota transplantation has emerged as a therapeutic strategy as well.
CONCLUSIONS: Nowadays, it is widely accepted that changes in the normal gut microbiome causing dysbiosis and immune dysregulation play a role gastroesophageal cancer. Different interventions, including probiotics and prebiotics intake are being developed to improve therapeutic outcomes and mitigate toxicities associated with anticancer treatment. Further studies are required in order to introduce the microbiome among the available tools of precision medicine in the field of anticancer treatment.
Participants will receive Itraconazole twice a day (BID) on Day 1 and once a day (QD) from Day 2 to Day 13. Participants will receive Divarasib in combination with Itraconazole on Day 5.
In one embodiment, a method of assembling a longitudinal database is provided. The method comprises receiving, using a processor of a data storage unit, medical data streams from a plurality of sources. The medical data streams include patient data related to a plurality of medical events. A first date range that indicates a time span associated with the patient is identified in view of the patient data. The medical events are normalized into a plurality of linking keys based on the first date range. The keys are adapted to longitudinally link each medical event in a sequence of occurrence. Each key of comprises an offset from a start date of the first date range for a corresponding medical event. The medical events are compressed in view of the keys. The compressing generates a location index for each medical event associated with the keys based on a corresponding offset.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having excellent steroid 5α-reductaseII- type-specific inhibitory effect, and useful in e.g. hair growth stimulants, anti- acnevulgaris bacteria skin drugs, by including a triterpene compound as active ingredient. SOLUTION: This inhibitor is obtained by including a compound of formula I (R is a 1-6C alkyl) (e.g. a compound of formula II) as active ingredient which is afforded by separation from extracts of plants such as cuachalalate; juliania adstringens, Amphiptery gumadstringens or the like, belonging to the family Julianiaceae. When this inhibitor is to be used in e.g. medicaments/quasi-drugs and cosmetic compositions, it is preferable that its daily dose is 4-10 ml and the above-mentioned extract (s) is included at 0.005-20 wt.% on a dry basis.
A functional mammalian growth factor receptor/yeast histidine kinase chimera in  Saccharomyces cerevisiae . In a preferred embodiment, the extracellular domain of the human epidermal growth factor receptor has been fused to the intracellular kinase domain of the SLN1 gene. The SLN1 gene encodes the plasma membrane sensor kinase of the yeast high osmolarity/glycerol response MAP kinase pathway. The chimeric protein is almost completely nonfunctional because the EGFR ECD is not capable of dimerization in the absence of ligand. In the presence of ligand, however, the chimeric kinase is activated and phosphorylation through the pathway is quantitatively repressed. This measure of pathway activity can be utilized to identify agonists and antagonists of the EGFR and other tyrosine kinase growth factor receptors in yeast cells.
Shift work is a prevalent workplace exposure, which increases the possibility of unhealthy behaviours and circadian rhythm disruptions and elevates the risk of metabolic diseases and adverse reproductive outcomes. But its potential of increasing the risk of postpartum weight retention remains uncertain. This study aimed to investigate the association between maternal shift work prior to conception and postpartum weight retention, and to identify modifiable factors during pregnancy for prevention. We analysed data from the Taiwan Birth Cohort Study, a prospective cohort of Taiwanese women who gave birth in 2005. We examined the pre-conceptional shift work status of 13,575 mothers and their body weight before pregnancy, before delivery, six and eighteen months after delivery. We used multivariable linear models to examine associations and effect modifications. Maternal shift work before pregnancy was significantly associated with increased postpartum weight retention at six and eighteen months (β-estimate for six months: 0.19-kilogram, 95% CI: 0.03-0.34; eighteen months: 0.23-kilogram, 95% CI: 0.04-0.40). The association between shift work and weight retention at six months postpartum was stronger among mothers who were overweight or obese before pregnancy than mothers with normal weight. This study showed the impact of shift work on postpartum weight retention and suggested a stronger association among mothers with overweight or obesity before pregnancy.
SEROQUEL is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years) [see Clinical Studies (14.2)].

SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [see Clinical Studies (14.2)].

SEROQUEL is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of SEROQUEL as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2)].
The three main chronic myeloproliferative disorders are polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). These are clonal neoplastic diseases characterized by proliferation of one or more hematopoietic lineages. Recently a mutation of the Janus Kinase 2 (JAK2) gene that leads to the substitution of phenylalanine for valine at position 617 of the JAK2 protein, JAK2 V617F, has been found in 76% to 97% of patients with PV, 29% to 57% of patients with ET and 50% of patients with IMF. This mutation confers constitutive activity on to the JAK2 protein and appears to play an important role in the pathobiology of these conditions. However, not all patients with myeloproliferative disorders have this mutation and it may not be the primary cause of these diseases. The primary goal of this prospective natural history study is to investigate the molecular basis of these diseases in groups of patients who have JAK2 V617F and in those who do not. A second goal is to identify biomarkers for PV and the other myeloproliferative disorders that are easier to measure than JAK2 V617F. Approximately, 150 patients with myeloproliferative disorders will be studied over 3 years. The studies will involve the collection of 40 mL to 50 mL of peripheral blood from each subject. The blood will be used to assess neutrophil gene and protein expression, gene polymorphisms, and plasma protein levels.
To provide a biocompatible membrane composite that can provide an environment that is able to mitigate or tailor the foreign body response.SOLUTION: The membrane composite contains a mitigation layer and a vascularization layer. A reinforcing component may optionally be included to provide support to and prevent distortion of the biocompatible membrane composite in vivo. The mitigation layer may be bonded or adhered to an implantable device and/or cell system. The biocompatible membrane composite may be used as a surface layer for implantable devices or cell systems that require vascularization for function but need protection from the host's immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite may partially or fully cover the exterior of the implantable devices or the cell systems. The mitigation layer is positioned between the implantable device or a bioactive scaffold and the vascularization layer.SELECTED DRAWING: Figure 7